Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
The co-founder of Regeneron has warned that blockbuster weight-loss drugs could cause “more harm than good” unless the rapid muscle loss associated with the treatments is solved, as the US biotech pushes ahead with trials of muscle-preserving medicines.
Clinical studies suggest that patients treated with the new class of weight- loss drugs, known as GLP-1s, lose…
Read the full article here